Starpharma s Viraleze registered for sale in India miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
MELBOURNE, Australia, June 11, 2021 /PRNewswire/ India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze following its registration
Scripps Research Institute testing shows Viraleze highly active against UK COVID strain
MELBOURNE, Australia, June 1, 2021 /PRNewswire/ Australia s Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19, reducing infectivity of the virus by >98%, it was announced today in a major development for the product.
Melbourne-based biopharmaceutical company Starpharma found there was no loss of potency compared to an earlier US strain of the virus, which is irreversibly inactivated by Viraleze within one minute of exposure.
The results hold out significant promise for the product given concerns with the public health impacts of new variants of SARS-CoV-2. Starpharma is also testing the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks. Testing of the Indian variant will also be undertaken when virus availability allows.
An Australian biotech company has joined the fight against coronavirus by launching an anti-viral nasal spray that s already available in the UK.
Starpharma first rolled out the product known as Viraleze in London at the end of March and it s currently being sold for the equivalent of A$27 in Lloyds Pharmacy chemists across the city.
The spray, which was developed in Melbourne, works by deactivating the virus as soon as it enters the nose, preventing the person using it from getting sick.
CEO of the company, Jackie Fairley, said the spray is best used once every six hours for up to 30 days - acting as a form of defence to the virus when social distancing is not possible.